Many additional effects in HIV pathogenesis are now described for the chemokine receptor CCR5, long recognized as an important coreceptor for HIV, and its ligand CCL3L1.
References
Lederman, M.M., Penn-Nicholson, A., Cho, M. & Mosier, D. J. Am. Med. Assoc. 296, 815–826 (2006).
Murphy, P.M. Fundamental Immunology, 5th edn. (ed. Paul, W.E.) 801–840 (Lippincott Williams and Wilkins, Philadelphia, 2003).
Gonzalez, E., et al. Science 307, 1434–1440 (2005).
Dolan, M.J. et al. Nat. Immunol. 8, 1324–1336 (2007).
Brenchley, J.M. et al. Nat. Med. 12, 1365–1371 (2006).
Deeks, S.G. et al. Blood 104, 942–947 (2004).
Giorgi, J.V. et al. J. Acquir. Immune Defic. Syndr. 6, 904–912 (1993).
Silvestri, G., Paiardini, M., Pandrea, I., Lederman, M.M. & Sodora, D.L. J. Clin. Invest. (in the press).
Pandrea, I. et al. Blood 109, 1069–1076 (2006).
Gonzalez, E. et al. Proc. Natl. Acad. Sci. USA 96, 12004–12009 (1999).
Glass, W.G. et al. J. Exp. Med. 203, 35–40 (2006).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lederman, M., Sieg, S. CCR5 and its ligands: a new axis of evil?. Nat Immunol 8, 1283–1285 (2007). https://doi.org/10.1038/ni1207-1283
Issue Date:
DOI: https://doi.org/10.1038/ni1207-1283
- Springer Nature America, Inc.